Immunotherapy and molecularly targeted therapy have become clinically validated treatments for many cancers. However, despite the increased success, immunotherapy and targeted therapy are far from perfect. The communities of commensal microbes that inhabit the surfaces exposed to the external environment intersect cancer therapy at multiple levels. Microbes can directly modulate the pharmacological properties of anticancer drugs and influence their efficacy. Alternatively, reciprocal cross-talks with the host may influence the anticancer immune response or the side effects associated with the cancer therapy. This special issue will focus on aspects related to the composition of the microbial communities as well as the production of microbial metabolites in immunotherapy and other forms of cancer therapy and welcome all key findings that can help to understand, predict, and balance their efficacy/safety profile in order to improve oncologic outcome.
Aimed topics can be, but are not confined to:
● Microbiome signatures associated with therapeutic efficacy and/or safety of immunotherapy and other forms of cancer therapy
● Microbial metabolites with the potential to influence the efficacy and/or safety of immunotherapy and other forms of cancer therapy
● Characterization of immune-microbial cross-talks in response to immunotherapy and other forms of cancer therapy
● Engineered tumor-targeting bacteria as therapeutic agents